Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19734420 | 1.00 | EPHX2 (0.37) | EPHX2NCF1CYP2D6CYP1A2NOS3 | |
| SCHEMBL24480776 | 1.00 | EPHX2 (0.37) | EPHX2NCF1CYP2D6CYP1A2NOS3 | |
| SCHEMBL19318044 | 1.00 | EPHX2 (0.37) | EPHX2NCF1CYP2D6CYP1A2NOS3 | |
| SCHEMBL19318047 | 1.00 | EPHX2 (0.37) | EPHX2NCF1CYP2D6CYP1A2NOS3 | |
| SCHEMBL19318045 | 1.00 | EPHX2 (0.37) | EPHX2NCF1CYP2D6CYP1A2NOS3 | |
| SCHEMBL22415178 | 0.95 | EPHX2 (0.37) | EPHX2NCF1CYP2D6CYP1A2NOS3 | |
| SCHEMBL26852981 | 0.90 | — | — | |
| SCHEMBL3538934 | 0.90 | — | — | |
| SCHEMBL26852980 | 0.90 | — | — | |
| SCHEMBL7135021 | 0.87 | EPHX2 (0.39) | EPHX2NCF1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3565861-B1 | PHOTOCURABLE HARDCOAT COMPOSITIONS, METHODS, AND ARTICLES DERIVED THEREFROM | BASF SE (DE) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023069884-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2021238834-A1 | ARYLFORMAMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2021-12-02 | — | — | WO | disclosed |
| US-20180217498-A1 | PHOTOACTIVABLE NITROGEN BASES | BASF SE (DE) | 2018-08-02 | — | — | US | disclosed |
| EP-3312209-A1 | SELF-HEALING COMPOSITION, SELF-HEALING FILM, AND DEVICE INCLUDING THE SELF-HEALING FILM | Samsung Electronics Co., Ltd. (KR) | 2018-04-25 | — | — | EP | disclosed |
| WO-2018025970-A1 | AMIDATE COMPOUND, CATALYST FOR POLYURETHANE PRODUCTION, AND METHOD FOR PRODUCING POLYURETHANE RESIN | 広栄化学工業株式会社 | 2018-02-08 | — | — | WO | disclosed |
| US-9796627-B2 | Epoxy-based substance for fixing purposes, the use thereof and the use of specific components | FISCHERWERKE GMBH & CO. KG (DE) | 2017-10-24 | — | — | US | disclosed |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | Epizyme, Inc. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160355437-A1 | EPOXY-BASED SUBSTANCE FOR FIXING PURPOSES, THE USE THEREOF AND THE USE OF SPECIFIC COMPONENTS | FISCHERWERKE GMBH & CO KG (DE) | 2016-12-08 | — | — | US | disclosed |
| US-20150307702-A1 | EPOXY-BASED SUBSTANCE FOR FIXING PURPOSES, THE USE THEREOF AND THE USE OF SPECIFIC COMPONENTS | FISCHERWERKE GMBH & CO. KG (DE) | 2015-10-29 | — | — | US | disclosed |
| US-20150105493-A1 | EPOXY COMPOUND HAVING ALKOXY SILYL GROUP, COMPOSITION COMPRISING SAME, CURED PRODUCT, USE THEREOF AND METHOD FOR PREPARING EPOXY COMPOUND HAVING ALKOXY SILYL GROUP | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2015-04-16 | — | — | US | disclosed |
| US-8906979-B2 | Macrophotoinitiators | BASF SE (DE) | 2014-12-09 | — | — | US | disclosed |
| EP-2562167-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES AS FUNGICIDES | Dow AgroSciences LLC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1773869-B9 | MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC (CA) | 2013-01-23 | — | — | EP | disclosed |
| US-20120178844-A1 | MACROPHOTOINITIATORS | BASF SE (DE) | 2012-07-12 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7220765-B2 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 2007-05-22 | — | — | US | disclosed |
| US-7199145-B2 | Derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D' 'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 2007-04-03 | — | — | US | disclosed |
| US-6872827-B2 | Somatostatin analogue compounds | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2005-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178844-A1 | MACROPHOTOINITIATORS | CD68, CD209, MSR1 | EPHX2 1465/4885NCF1 830/4885CYP2D6 616/4885 |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | EPHX2 2219/4885NCF1 1755/4885CYP2D6 4852/4885 |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | SMYD3, SMYD2, SMURF2 | EPHX2 3312/4885NCF1 1995/4885CYP2D6 3847/4885 |
| US-20180217498-A1 | PHOTOACTIVABLE NITROGEN BASES | CBR1, NR0B1, NR0B2 | EPHX2 2480/4885NCF1 1658/4885CYP2D6 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.